IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2773
-0.0097 (-3.38%)
Jan 29, 2026, 4:00 PM EST - Market closed
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
26.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% | 70 | 0 |
| Mar 31, 2024 | 67 | 6 | 9.84% | 67 | 0 |
| Mar 31, 2023 | 61 | 9 | 17.31% | 61 | 0 |
| Mar 31, 2022 | 52 | 2 | 4.00% | 52 | 0 |
| Mar 31, 2021 | 50 | 0 | - | 50 | 0 |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| Boundless Bio | 64 |
| Senti Biosciences | 34 |
| Palatin Technologies | 29 |
| Daré Bioscience | 23 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Rallybio | 15 |
IGC News
- 7 days ago - IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York - Accesswire
- 17 days ago - IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia - Accesswire
- 23 days ago - IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Accesswire
- 24 days ago - IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - Accesswire
- 5 weeks ago - IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Accesswire
- 6 weeks ago - IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Accesswire
- 7 weeks ago - IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. - Accesswire
- 7 weeks ago - IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - Accesswire